When patients were subdivided into those without hepatic steatosis (31 men/9 women), those without evidence of FDG‐avid malignancy on PET/CT (15/6), and those without either (11/5), gender differences in hepatic MRglu remained highly significant, but there were no significant differences in CT density, blood glucose, BMI, or recent chemotherapy history.
1
—
—